InMed Pharmaceuticals Inc

For the period ended Jun 30, 2024. Filed Sep 30, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Sep 30, 2024

INM$15.56+17.8%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Shareholders’ Equity

For the years ended June 30, 2024 and 2023

Common Shares · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total
	#	$	$	$	$	$
Balance July 1, 2023	3,328,191	77,620,252	35,741,115	(101,400,209)	128,569	12,089,727
Private placement	3,272,733	3,240,006	1,976,188	-	-	5,216,194
Share issuance costs			(562,151)			(562,151)
Exercise of pre-funded warrants	2,318,032	1,924,142	(1,923,967)	-	-	175
Loss for the period	-	-	-	(7,675,550)	-	(7,675,550)
Share-based compensation	-	-	137,714	-	-	137,714
Balance June 30, 2024	8,918,956	82,784,400	35,368,899	(109,075,759)	128,569	9,206,109

Common Shares · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total
	#	$	$	$	$	$
Balance July 1, 2022	650,667	70,718,461	31,684,098	(93,452,587)	128,569	9,078,541
Private placement	240,000	673,748	11,326,042	-	-	11,999,790
Share issuance costs	-	(115,955)	(1,895,311)	-	-	(2,011,266)
Agents’ investment options	-	-	691,483	-	-	691,483
Exercise of pre-funded warrants	2,437,524	6,343,998	(6,343,352)	-	-	646
Loss for the period	-	-	-	(7,947,622)	-	(7,947,622)
Share-based compensation	-	-	278,155	-	-	278,155
Balance June 30, 2023	3,328,191	77,620,252	35,741,115	(101,400,209)	128,569	12,089,727

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.